for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biosearch SA

BIOS.MC

Latest Trade

0.95EUR

Change

-0.01(-1.35%)

Volume

177,301

Today's Range

0.93

 - 

0.98

52 Week Range

0.89

 - 

1.70

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
0.96
Open
0.95
Volume
177,301
3M AVG Volume
2.61
Today's High
0.98
Today's Low
0.93
52 Week High
1.70
52 Week Low
0.89
Shares Out (MIL)
57.19
Market Cap (MIL)
54.81
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Biosearch 9-Month EBITDA Down At 1.5 Mln Euros YoY

Biosearch Names Ignacio Elola Zaragueta As New Chairman

Biosearch Invests 0.7 Mln Euros In Research For Old Age Conditions

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biosearch SA

Biosearch SA, formerly Puleva Biotech SA, is a Spain-based company primarily engaged in the research, development and commercialization of functional food products based on natural ingredients aimed at the consecution of health positive effects that may improve the quality of life. The Company specializes in the nutrition research, which includes patents on infant formulas; the process for extraction and purification of Omega-3 acids; biotechnology projects focused on the microbial fermentation, enzymatic transformations and purification of functional lipids, and the development of functional dairy products, healthy fats, probiotics bacteria and antioxidants, among others, which are distributed under the Eupoly-Epa and Hereditum brands.

Industry

Biotechnology & Drugs

Contact Info

C/ Camino de Purchil, 66

+34.958.240152

http://www.biosearchlife.com

Executive Leadership

Aurelio Antuna Rodriguez

Chairman of the Board

Loreto Huertas de la Camara

Chief Financial Officer

Alejandro Jara Garcia Navas

Chief Operating Officer

Jose Maria Roset Monros

General Director

Emma Madrid Sanchez-Gomez

Director of Human Resources

Key Stats

Revenue (MM, EUR)

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2018

0.060

2019(E)

0.020
Price To Earnings (TTM)
27.66
Price To Sales (TTM)
2.24
Price To Book (MRQ)
2.32
Price To Cash Flow (TTM)
15.51
Total Debt To Equity (MRQ)
7.20
LT Debt To Equity (MRQ)
2.60
Return on Investment (TTM)
7.66
Return on Equity (TTM)
6.08

Latest News

Latest News

BRIEF-Biosearch Signs Manufacturing And Supply Deal With Nestle

* SAYS IT SIGNS MANUFACTURING AND SUPPLY AGREEMENT WITH NESTLE FOR PATENTED PRODUCT "HEREDITUM LACTOBACILLUS FERMENTUM LC40®"

BRIEF-Biosearch Q1 EBITDA At 1.3 Mln Euros

Biosearch SA: * SAID ON FRIDAY Q1 REVENUE 6.2 MILLION EUROS * Q1 EBITDA 1.3 MILLION EUROS * Q1 PROFIT BEFORE TAX 880,000 EUROS Source text: https://bit.ly/2raXP04 Further company coverage: (Gdynia Newsroom)

BRIEF-Biosearch FY Net Result Turns To Profit Of 2 Mln Euros

* FY NET PROFIT 2.0 MILLION EUROS VERSUS LOSS 3.3 MILLION EUROS YEAR AGO

BRIEF-Biosearch signs 10-year license agreement with Nestlé

* SAID ON THURSDAY SIGNED LICENSE AND SUPPLY AGREEMENT WITH NESTLÉ UNIT NESTEC FOR ITS LACTOBACILLUS FERMENTUM LC40 STRAIN

BRIEF-Biosearch Seeks Patent on Fertility Improvement In Women With Polycystic Ovary Syndrome

* APPLIES FOR PATENT ON METHOD TO IMPROVE FERTILITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME

BRIEF-Biosearch reports 9-month EBITDA of 2.7 mln euros

BIOSEARCH SA: * 9-MONTH EBITDA 2.7 MILLION EUROS * 9-MONTH PROFIT BEFORE TAX 1.1 MILLION EUROS * 9-MONTH REVENUE 17.2 MILLION EUROS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-EFSA rejects probiotic application submitted by Biosearch Life

* THE EUROPEAN FOOD SAFETY AUTHORITY (EFSA) REJECTS HEREDITUM LC40 PROBIOTIC APPLICATION SUBMITTED BY BIOSEARCH LIFE Source text: http://bit.ly/2tYXSvu

BRIEF-Biosearch H1 EBITDA down 6.5 pct at 1.6 mln euros YoY

* H1 EBITDA DOWN 6.5 PERCENT AT 1.6 MILLION EUROS VERSUS YEAR AGO

BRIEF-Biosearch Q1 EBITDA up 1.1 percent at 660,000 euros yoy

* Q1 PROFIT BEFORE TAX 120,000 EUROS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biosearch FY net loss widens to 3.3 mln euros

* Reported on Monday FY net sales of 22.8 million euros ($24.1 million) versus 19.2 million euros year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up